Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Terminated × tazemetostat × Clear all

Phase

Phase 1 4 Phase 2 2 Phase 1/2 1

Status

Active not recruiting 5 Withdrawn 3 Not yet recruiting 2 Completed 2 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 74 Carboplatin 59 Cyclophosphamide 56 Nivolumab 50 Paclitaxel 47 Gemcitabine 43 Cisplatin 43 Dexamethasone 40 Radiotherapy 35 Rituximab 31 Capecitabine 31 Docetaxel 28 Bevacizumab 28 fludarabine 26 atezolizumab 25 avelumab 24 Cytarabine 24 Trastuzumab 23 Oxaliplatin 23 Lenalidomide 23 Cetuximab 23 Fluorouracil 22 Azacitidine 22 venetoclax 21 Temozolomide 21 Ipilimumab 21 130-nm albumin-bound paclitaxel 21 Filgrastim 20 Bortezomib 20 Albumin-Bound Paclitaxel 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04179864 2026-03-10

CELLO-1

Ipsen

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡